INTRODUCTION: Radiation Therapy Oncology Group 97-14 concluded that a single fraction of radiation was as effective in relieving pain as multiple fractions in the treatment of patients with bone metastases. A statistically significant higher retreatment rate, however, was noted in patients undergoing a single fraction treatment. The purpose of the analysis was to determine whether multiple fraction treatment is cost-effective in treating patients with bone metastasis, by preventing further retreatment. METHODS AND MATERIAL: A Markov model was used to evaluate the cost-effectiveness of 30 Gy in 10 fractions in comparison with 8 Gy in 1 fraction. Transition probabilities, cost, and utilities were obtained from the clinical trial. Costs and outcomes were not discounted because of the short time line for the study. RESULTS: The expected mean cost and quality-adjusted survival in months for patients receiving 8 Gy in 1 fraction and 30 Gy in 10 fractions was 998 US dollars and 7.26 months and 2316 US dollars and 9.53 months, respectively. The incremental cost-effectiveness ratio was 6973 US dollars/quality-adjusted life year. The results were sensitive to the utility of the posttreatment state for both single and multiple fraction treatments. CONCLUSION: Single fraction treatment was the less expensive treatment in the treatment of patients with bone metastasis treated on Radiation Therapy Oncology Group 97-14.
INTRODUCTION: Radiation Therapy Oncology Group 97-14 concluded that a single fraction of radiation was as effective in relieving pain as multiple fractions in the treatment of patients with bone metastases. A statistically significant higher retreatment rate, however, was noted in patients undergoing a single fraction treatment. The purpose of the analysis was to determine whether multiple fraction treatment is cost-effective in treating patients with bone metastasis, by preventing further retreatment. METHODS AND MATERIAL: A Markov model was used to evaluate the cost-effectiveness of 30 Gy in 10 fractions in comparison with 8 Gy in 1 fraction. Transition probabilities, cost, and utilities were obtained from the clinical trial. Costs and outcomes were not discounted because of the short time line for the study. RESULTS: The expected mean cost and quality-adjusted survival in months for patients receiving 8 Gy in 1 fraction and 30 Gy in 10 fractions was 998 US dollars and 7.26 months and 2316 US dollars and 9.53 months, respectively. The incremental cost-effectiveness ratio was 6973 US dollars/quality-adjusted life year. The results were sensitive to the utility of the posttreatment state for both single and multiple fraction treatments. CONCLUSION: Single fraction treatment was the less expensive treatment in the treatment of patients with bone metastasis treated on Radiation Therapy Oncology Group 97-14.
Authors: Wilbert B van den Hout; Yvette M van der Linden; Elsbeth Steenland; Ruud G J Wiggenraad; Job Kievit; Hanneke de Haes; Jan Willem H Leer Journal: J Natl Cancer Inst Date: 2003-02-05 Impact factor: 13.506
Authors: Katharine Johnston; Alastair Gray; Michael Moher; Patricia Yudkin; Lucy Wright; David Mant Journal: Int J Technol Assess Health Care Date: 2003 Impact factor: 2.188
Authors: E Steenland; J W Leer; H van Houwelingen; W J Post; W B van den Hout; J Kievit; H de Haes; H Martijn; B Oei; E Vonk; E van der Steen-Banasik; R G Wiggenraad; J Hoogenhout; C Wárlám-Rodenhuis; G van Tienhoven; R Wanders; J Pomp; M van Reijn; I van Mierlo; E Rutten; J Leer; T van Mierlo Journal: Radiother Oncol Date: 1999-08 Impact factor: 6.280
Authors: William F Hartsell; Charles B Scott; Deborah Watkins Bruner; Charles W Scarantino; Robert A Ivker; Mack Roach; John H Suh; William F Demas; Benjamin Movsas; Ivy A Petersen; Andre A Konski; Charles S Cleeland; Nora A Janjan; Michelle DeSilvio Journal: J Natl Cancer Inst Date: 2005-06-01 Impact factor: 13.506
Authors: Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar Journal: J Clin Oncol Date: 2007-04-23 Impact factor: 44.544
Authors: B Rasmusson; I Vejborg; A B Jensen; M Andersson; A M Banning; T Hoffmann; P Pfeiffer; H K Nielsen; P Sjøgren Journal: Radiother Oncol Date: 1995-03 Impact factor: 6.280
Authors: Sanders Chang; Peter May; Nathan E Goldstein; Juan Wisnivesky; Kenneth Rosenzweig; R Sean Morrison; Kavita V Dharmarajan Journal: J Palliat Med Date: 2017-11-30 Impact factor: 2.947
Authors: Aileen B Chen; Angel Cronin; Jane C Weeks; Elizabeth A Chrischilles; Jennifer Malin; James A Hayman; Deborah Schrag Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: J O Kim; N Hanumanthappa; Y T Chung; J Beck; R Koul; B Bashir; A Cooke; A Dubey; J Butler; M Nashed; W Hunter; A Ong Journal: Curr Oncol Date: 2020-08-01 Impact factor: 3.677
Authors: Matthew Koshy; Renuka Malik; Usama Mahmood; Zain Husain; Ralph R Weichselbaum; David J Sher Journal: J Natl Cancer Inst Date: 2015-09-30 Impact factor: 13.506
Authors: Liang Zeng; Edward Chow; Liying Zhang; Shaelyn Culleton; Lori Holden; Florencia Jon; Luluel Khan; May Tsao; Elizabeth Barnes; Cyril Danjoux; Arjun Sahgal Journal: Support Care Cancer Date: 2011-04-08 Impact factor: 3.603